ESTRO 2025 - Abstract Book

S966

Clinical – Head & neck

ESTRO 2025

Late local (LLF), regional (LRF) and distant (LDM) failure and newly observed late grade≥3 toxicity were defined as occurring >3 years after treatment. All recurrent HNC overlapping with >50% of the initial GTV’s were considered as local/regional failure. Overall (OS) was defined as death from any cause. Disease-free survival (DFS) was defined as death from any cause or LF, RF or DM, whichever comes first. Results: At analysis, 24 (51%) and 19 (40%) patients were alive in A-DPBN and S-IMRT, respectively. Median time of follow-up (in living patients) is 95 months. There was a trend of higher local control after A-DPBN as compared to S-IMRT at 5 years (82% vs. 65% [p=0.08]). There was no difference in 5-year regional control between the groups (79% after A-DPBN vs. 82% after S-IMRT, p=0.9). There was a non-significant trend of higher distant control after A-DPBN (79% vs. 89% [ p =0.086], respectively). (Figure 2).